Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
2 Months : From Oct 2019 to Dec 2019
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Michael Gutch, Chief Business Officer and Chief Financial Officer, will be hosting a fireside chat at the 28th Annual Credit Suisse Healthcare Conference being held November 11-13, 2019 in Scottsdale, AZ.
|Details of the presentation are below:|
|Event: ||28th Annual Credit Suisse Healthcare Conference |
|Location: ||The Phoenician|
|Date: ||Tuesday, November 12, 2019|
|Time: ||4:45 – 5:15 PM MST|
Additionally, Dr. Gutch will hold 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Company management should contact their Credit Suisse representatives.
About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.
Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 firstname.lastname@example.org
Investor Relations Contact Tram Bui The Ruth Group (646) 536-7035 email@example.com
Media ContactKirsten ThomasThe Ruth Group(508) firstname.lastname@example.org